Acquisition of multidrug resistance by L1210 leukemia cells decreases their tumorigenicity and enhances their susceptibility to the host immune response

[1]  H. Verschueren,et al.  Tumorigenicity of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Kk antigens , 2005, Clinical & Experimental Metastasis.

[2]  J. González-Ros,et al.  Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors , 2003, International journal of cancer.

[3]  Xiao-xiang Zheng,et al.  A flow cytometry-based assay for quantitative analysis of cellular proliferation and cytotoxicity in vitro. , 2002, Journal of immunological methods.

[4]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[5]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[6]  J. Jaffrezou,et al.  Signaling pathways activated by daunorubicin. , 2001, Blood.

[7]  M. Davey,et al.  The drug resistance proteins, multidrug resistance-associated protein and P-glycoprotein, do not confer resistance to Fas-induced cell death. , 2001, Cytometry.

[8]  M. Davey,et al.  Drug resistance does not correlate with resistance to Fas-mediated apoptosis. , 2001, Leukemia research.

[9]  D. Olive,et al.  Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. , 2000, Cancer research.

[10]  T. Blankenstein,et al.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.

[11]  F. Lacombe,et al.  Flow cytometric evaluation of fas expression in relation to response and resistance to anthracyclines in leukemic cells. , 2000, Cytometry.

[12]  G. Gherardi,et al.  Interferon-gamma up-regulates expression and activity of P-glycoprotein in human peripheral blood monocyte-derived macrophages. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[13]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[14]  W. Dalton,et al.  Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. , 1999, Blood.

[15]  M. Nagarkatti,et al.  Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells. , 1998, Blood.

[16]  R. Johnstone,et al.  The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Guoyou Chen,et al.  Involvement of MHC class I molecule and ICAM-1 in the enhancement of adhesion and cytotoxic susceptibility to immune effector cells of tumor cells transfected with the interleukin (IL)-2, IL-4 or IL-6 gene , 1997, Journal of Cancer Research and Clinical Oncology.

[18]  Y. Komada,et al.  Cytotoxic T‐lymphocytes recognizing P‐glycoprotein in murine multidrug‐resistant leukemias , 1997, European journal of haematology.

[19]  W. Dalton,et al.  Selection for drug resistance results in resistance to Fas-mediated apoptosis. , 1997, Blood.

[20]  J. Neefjes,et al.  Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. , 1996, British Journal of Cancer.

[21]  B. Seliger,et al.  Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. , 1996, Experimental hematology.

[22]  G. Raghu,et al.  The multidrug resistance phenotype confers immunological resistance , 1996, The Journal of experimental medicine.

[23]  W T Bellamy,et al.  P-glycoproteins and multidrug resistance. , 1996, Annual review of pharmacology and toxicology.

[24]  I. Fichtner,et al.  Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity. , 1994, Anticancer research.

[25]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[26]  J. González-Ros,et al.  Possible coexistence of two independent mechanisms contributing to anthracycline resistance in leukaemia P388 cells. , 1993, European journal of cancer.

[27]  J. González-Ros,et al.  Rapid kinetics of the interaction between daunomycin and drug‐sensitive or drug‐resistant P388 leukemia cells , 1992, FEBS letters.

[28]  I. Roninson.  The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. , 1992, Biochemical pharmacology.

[29]  T. Grogan,et al.  Altered expression of P‐glycoprotein and cellular adhesion molecules on human multi‐drug‐resistant tumor cells does not affect their susceptibility to NK‐ and LAK‐mediated cytotoxicity , 1991, International journal of cancer.

[30]  V. Ling,et al.  Resistance of multidrug‐resistant lines to natural killer‐like cell‐mediated cytotoxicity , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  H. Fuji,et al.  Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies. , 1983, Cancer research.

[32]  M. Murakami,et al.  Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. III. Control of host resistance to drug-resistant L1210 sublines by H-2-linked and non-H-2-linked genes. , 1983, Journal of the National Cancer Institute.